ARA-290 for Carpal Tunnel: Human Trial Data on Nerve Symptoms and Fiber Density
Nerves can break down after compression or injury. Carpal tunnel involves pressure on the median nerve. If breakdown outruns repair, symptoms persist. ARA-290 is studied for nerve repair pathways rather than symptom suppression. ARA-290 is
Regeneration vs degeneration — where this fits
Nerves can break down after compression or injury. Carpal tunnel involves pressure on the median nerve. If breakdown outruns repair, symptoms persist. ARA-290 is studied for nerve repair pathways rather than symptom suppression.
What it is
ARA-290 is a peptide derived from erythropoietin. It does not raise red blood cells. It targets the innate repair receptor.
How it works
Step 1: The peptide binds the innate repair receptor. Step 2: Binding activates repair signals in nerve tissue. Step 3: Signals support nerve fiber maintenance and symptom change in some models.
Why it would work (logic chain)
If the receptor controls repair, then binding it may increase nerve fiber density. If density increases, then symptoms tied to low density may decrease. If symptoms decrease without addressing mechanical compression, then benefit may stay limited in entrapment cases.
Why people take it
People take it when they seek nerve repair options beyond standard symptom relief. Some have carpal tunnel confirmed by EMG. Some have other neuropathies.
How many people take it
Unknown. The ledger records nine sources total. No population count exists.
One phase 2 human trial in type 2 diabetes patients with neuropathy gave 4 mg daily for 28 days (source s1). Neuropathic symptoms on PainDetect improved in the ARA-290 group. Corneal nerve fiber density rose by +2.6 ± 1.0 fibers/mm² in the treatment subgroup (n=18, p=0.02). A linear link appeared between density change and symptom change.
A review notes rat data where ARA-290 gave long-lasting neuropathic pain relief (source s2).
No human trial of ARA-290 in carpal tunnel exists (claim c3). Effects seen in diabetic neuropathy may not transfer to compression neuropathy (claim c20).
What people say on Reddit
One user with tarsal tunnel (analogous to carpal tunnel) reported no benefit for compression pain but noted positive axonal repair in a different injury after two months (source s3).
Another user stated nerve damage boundaries shrank several inches in weeks and attributed the change to ARA-290 (source s4).
Multiple users reported painful pins and needles flares at 2–4 mg and stopped early; one linked sensitivity to Sjögren’s (source s5).
One user with EMG-confirmed carpal tunnel and multi-site neuropathy planned a 28-day cycle at 3–6 mg/day but reported no outcome yet (source s6).
One post described ARA-290 as a nerve healing peptide for conditions including carpal tunnel and asked for experiences (source s7).
What people say on X
One user sought results for carpal tunnel use and reported receiving a bad batch with floating clouds (source s8).
One user with severe work-induced carpal tunnel asked where to buy ARA-290 (source s9).
What we do not know
No human trials test ARA-290 specifically in carpal tunnel. It is unknown if diabetic neuropathy findings apply to mechanical compression cases. Long-term efficacy and safety data for chronic nerve conditions are absent.
Safety and limits
The ledger records short-term human data only. Some users reported painful nerve flares leading to early stop. No population safety data exist.
Anybody try ARA-290 peptide for nerve damage?“I also have tarsal tunnel syndrome, which is the ankle version of carpal tunnel syndrome; my tibial nerve is entrapped in scar tissue from a surgery. Because that nerve pain is caused by mechanical compression, I don't expect the peptide to help (and so far it has not).”
Anybody try ARA-290 peptide for nerve damage?“The boundaries of my nerve damage have shrunk several inches! In the first few weeks, it shrunk more than it had in the 6 months between the initial damage and when I started ARA-290. ... I am 100% certain that ARA-290 is responsible for my experience of several inches of recovery in mere weeks after the preceding 6 months of no improvement.”
Peptide ARA-290 : r/neuropathy“I titrated up 0.5 mg, 1 mg, 2 mg, 3 mg and finally 4 mg. At 3 and 4 milligrams I experienced painful pins and needles in my heels so I had to stop. ... I began last week at .5 mg, then 1, then 2, then 3 and finally 4 mg. I tittered slowly up due to my Sjogren's disease. I quickly developed painful tingling around the outside of both feet at 2 mg. Those last 3 days were very painful. ... I tried AR”
ARA-290 Disc Herniaton & Nerve Pain : r/neuropathy“Periphial neuropathy in hands/shoulder (emg showed carpal tunnel and medial nerve damage) feet and legs to lower back (3 fusions, lt knee replacement, rt hip replacement and waiting on rt knee replacement).”
X post by @I_Research_Pept“Has anyone out there tried ARA-290? If so, what were you treating and what were the results? I never hear about this peptide, but want to try it for carpal tunnel. I purchased 7 vials from a vendor, but unfortunately, they were bad (floating clouds) and I have not repurchased yet”
X post by @SEpilogueG“Where do I buy these, specifically ARA-290? I have severe work induced carpal tunnel.”
the whole object this page is drawn from, as JSON
{
"schema":"https://miscsubjects.com/schemas/jarticle.json",
"status":"published",
"slug":"ara-290-carpal-tunnel",
"title":"ARA-290 for Carpal Tunnel: Human Trial Data on Nerve Symptoms and Fiber Density",
"kind":"source_ledger",
"summary":"Nerves can break down after compression or injury. Carpal tunnel involves pressure on the median nerve. If breakdown outruns repair, symptoms persist. ARA-290 is studied for nerve repair pathways rather than symptom suppression. ARA-290 is",
"created":"2026-06-29T13:21:20.067Z",
"body": [
"## Regeneration vs degeneration — where this fits\nNerves can break down after compression or injury. Carpal tunnel involves pressure on the median nerve. If breakdown outruns repair, symptoms persist. ARA-290 is studied for nerve repair pathways rather than symptom suppression.\n\n## What it is\nARA-290 is a peptide derived from erythropoietin. It does not raise red blood cells. It targets the innate repair receptor.\n\n## How it works\nStep 1: The peptide binds the innate repair receptor. \nStep 2: Binding activates repair signals in nerve tissue. \nStep 3: Signals support nerve fiber maintenance and symptom change in some models.\n\n## Why it would work (logic chain)\nIf the receptor controls repair, then binding it may increase nerve fiber density. If density increases, then symptoms tied to low density may decrease. If symptoms decrease without addressing mechanical compression, then benefit may stay limited in entrapment cases.\n\n## Why people take it\nPeople take it when they seek nerve repair options beyond standard symptom relief. Some have carpal tunnel confirmed by EMG. Some have other neuropathies.\n\n## How many people take it\nUnknown. The ledger records nine sources total. No population count exists.\n\n## Evidence inventory\nSources total: 9. \nHuman studies: 1. \nAnimal studies: 1 (via review). \nAnecdotal sources: 7 (5 Reddit, 2 X). \nClaims human: 4. \nClaims preclinical: 4. \nClaims anecdotal: 9.\n\n## What scientists say\nOne phase 2 human trial in type 2 diabetes patients with neuropathy gave 4 mg daily for 28 days (source s1). Neuropathic symptoms on PainDetect improved in the ARA-290 group. Corneal nerve fiber density rose by +2.6 ± 1.0 fibers/mm² in the treatment subgroup (n=18, p=0.02). A linear link appeared between density change and symptom change. \n\nA review notes rat data where ARA-290 gave long-lasting neuropathic pain relief (source s2). \n\nNo human trial of ARA-290 in carpal tunnel exists (claim c3). Effects seen in diabetic neuropathy may not transfer to compression neuropathy (claim c20).\n\n## What people say on Reddit\nOne user with tarsal tunnel (analogous to carpal tunnel) reported no benefit for compression pain but noted positive axonal repair in a different injury after two months (source s3). \n\nAnother user stated nerve damage boundaries shrank several inches in weeks and attributed the change to ARA-290 (source s4). \n\nMultiple users reported painful pins and needles flares at 2–4 mg and stopped early; one linked sensitivity to Sjögren’s (source s5). \n\nOne user with EMG-confirmed carpal tunnel and multi-site neuropathy planned a 28-day cycle at 3–6 mg/day but reported no outcome yet (source s6). \n\nOne post described ARA-290 as a nerve healing peptide for conditions including carpal tunnel and asked for experiences (source s7).\n\n## What people say on X\nOne user sought results for carpal tunnel use and reported receiving a bad batch with floating clouds (source s8). \n\nOne user with severe work-induced carpal tunnel asked where to buy ARA-290 (source s9).\n\n## What we do not know\nNo human trials test ARA-290 specifically in carpal tunnel. It is unknown if diabetic neuropathy findings apply to mechanical compression cases. Long-term efficacy and safety data for chronic nerve conditions are absent.\n\n## Safety and limits\nThe ledger records short-term human data only. Some users reported painful nerve flares leading to early stop. No population safety data exist."
],
"facts": {
"converted_from":"markdown",
"original_updated":"2026-06-29T20:56:06.185Z",
"register":"source_ledger",
"category":null
},
"sources": [
{
"id":"s1",
"type":"pubmed",
"url":"https://pmc.ncbi.nlm.nih.gov/articles/PMC4365069/",
"title":"ARA 290, a Nonerythropoietic Peptide Engineered from Erythropoietin, Improves Metabolic Control and Neuropathic Symptoms in Patients with Type 2 Diabetes",
"quote":"Neuropathic symptoms as assessed by the PainDetect questionnaire improved significantly in the ARA 290 group... In this group, a linear relationship existed between the observed change in CNFD and the change in symptoms... mean change in of +2.6 ± 1.0 fibers/mm² for ARA 290 (n = 18; p = 0.02)",
"summary":"Phase 2 RCT: 4 mg SC daily ×28 d improved symptoms and CNFD in diabetic neuropathy subgroup.",
"claim_ids": [
"c1",
"c2",
"c17",
"c20",
"c23",
"c24"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T08:54:05.451Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"genesis",
"hash":"e64b5c5b9b99fedac01e106e9d8ffbcbfe2ce99bb6731ad21bdec8ded6bd7d02",
"source_role":"cycle_background",
"quote_sha256":"7bcdc804641dedb7c1ef9ff77e2fe9e070b33bfee1d13426217c7810bc17b3ef"
},
{
"id":"s2",
"type":"review",
"url":"https://journals.lww.com/painrpts/fulltext/2016/08000/targeting_the_innate_repair_receptor_to_treat.2.aspx",
"title":"Targeting the innate repair receptor to treat neuropathy",
"quote":"Swartjes and colleagues... showed that ARA-290 produced long-lasting relief of neuropathic pain in rats",
"summary":"Reviews preclinical rat data on neuropathic pain relief.",
"claim_ids": [
"c4",
"c23"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T08:54:05.451Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"e64b5c5b9b99fedac01e106e9d8ffbcbfe2ce99bb6731ad21bdec8ded6bd7d02",
"hash":"87b2b0e93471913b76c356312f02e7fc53bbcd538645f23089f7fba577b2f3ba",
"source_role":"mechanism_support",
"quote_sha256":"35d2ac47c830998979e2164b307e1af382ab79fd1036281e74eb0a41efae23c4"
},
{
"id":"s3",
"type":"reddit",
"url":"https://www.reddit.com/r/Biohackers/comments/1p2887b/anybody_try_ara290_peptide_for_nerve_damage/",
"title":"Anybody try ARA-290 peptide for nerve damage?",
"quote":"I also have tarsal tunnel syndrome, which is the ankle version of carpal tunnel syndrome; my tibial nerve is entrapped in scar tissue from a surgery. Because that nerve pain is caused by mechanical compression, I don't expect the peptide to help (and so far it has not).",
"summary":"User reports no benefit for tarsal tunnel (compression neuropathy analogous to carpal tunnel) but positive axonal repair in another nerve injury after 2 months at 5mg/day.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c5",
"c18",
"c21"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T12:01:19.346Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"87b2b0e93471913b76c356312f02e7fc53bbcd538645f23089f7fba577b2f3ba",
"hash":"8a505d8fb61a169cd1265a1b51d2b90dc92e539fd2a208f1e89a412f3021374b",
"source_role":"anecdotal_report",
"quote_sha256":"aa11f7d3fc857a1981a91977060814032a798f37236ec09e32277d7c69c5b694"
},
{
"id":"s4",
"type":"reddit",
"url":"https://www.reddit.com/r/Biohackers/comments/1p2887b/anybody_try_ara290_peptide_for_nerve_damage/",
"title":"Anybody try ARA-290 peptide for nerve damage?",
"quote":"The boundaries of my nerve damage have shrunk several inches! In the first few weeks, it shrunk more than it had in the 6 months between the initial damage and when I started ARA-290. ... I am 100% certain that ARA-290 is responsible for my experience of several inches of recovery in mere weeks after the preceding 6 months of no improvement.",
"summary":"Positive user experience repairing axonal nerve damage with ARA-290; notes it did not help compression-related tarsal tunnel pain.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c6",
"c18",
"c21"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T12:01:19.346Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"8a505d8fb61a169cd1265a1b51d2b90dc92e539fd2a208f1e89a412f3021374b",
"hash":"c357ecd533dfadcd98944b895bf7890cd83a5e4eaa9be966212ebfeed01ec109",
"source_role":"adjacent_context",
"quote_sha256":"9f1a984d0950285a28ca2b5c529f45a4f86207cca659a331977a3cb8e6de352d"
},
{
"id":"s5",
"type":"reddit",
"url":"https://www.reddit.com/r/neuropathy/comments/1o33123/peptide_ara290/",
"title":"Peptide ARA-290 : r/neuropathy",
"quote":"I titrated up 0.5 mg, 1 mg, 2 mg, 3 mg and finally 4 mg. At 3 and 4 milligrams I experienced painful pins and needles in my heels so I had to stop. ... I began last week at .5 mg, then 1, then 2, then 3 and finally 4 mg. I tittered slowly up due to my Sjogren's disease. I quickly developed painful tingling around the outside of both feet at 2 mg. Those last 3 days were very painful. ... I tried ARA290 last October and had to quit after 6 days.",
"summary":"Multiple users report bad outcomes with ARA-290 causing painful nerve flares/pins and needles, leading them to stop treatment early despite trying titration for neuropathy (one mentions autoimmune-related sensitivity).",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c7",
"c18",
"c21"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T12:06:47.277Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"c357ecd533dfadcd98944b895bf7890cd83a5e4eaa9be966212ebfeed01ec109",
"hash":"d98046bdd43416e6a32b464a52272f868abfaced64e9c9f8682caee95eb22451",
"source_role":"adjacent_context",
"quote_sha256":"a80a3a982a5fe06d8d2c8dc42498cbdc7de0563f0bf135cbef5eefb662640dcf"
},
{
"id":"s6",
"type":"reddit",
"url":"https://www.reddit.com/r/neuropathy/comments/1tvw5x6/ara290_disc_herniaton_nerve_pain/",
"title":"ARA-290 Disc Herniaton & Nerve Pain : r/neuropathy",
"quote":"Periphial neuropathy in hands/shoulder (emg showed carpal tunnel and medial nerve damage) feet and legs to lower back (3 fusions, lt knee replacement, rt hip replacement and waiting on rt knee replacement).",
"summary":"User with confirmed carpal tunnel (via EMG) and other neuropathy planning 28+ day ARA-290 cycle at 3-6mg/day for nerve pain, no outcome reported yet but notes interest in honest results.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c8",
"c18",
"c21"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T12:06:47.277Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"d98046bdd43416e6a32b464a52272f868abfaced64e9c9f8682caee95eb22451",
"hash":"cc7b287dc3194fd4866501bc3f106fdfaace54e007b68412565b6243e9fceced",
"source_role":"anecdotal_report",
"quote_sha256":"d17b5527e59fcfa9d91641e6874f5414e4fd3905dd86e72a230374c54cfa14e0"
},
{
"id":"s7",
"type":"reddit",
"url":"https://www.reddit.com/r/tinnitus/comments/1papfky/anyone_try_ara290_peptide_for_this_tinnitus/",
"title":"Anyone try ARA290 peptide for this tinnitus? : r/tinnitus",
"quote":"It's a nerve healing peptide known to regenerate nerves like sciatica and carpal tunnel syndrome ...",
"summary":"Post discusses ARA-290 as potential for nerve regeneration including carpal tunnel syndrome, seeking user experiences (no detailed personal outcomes in snippet).",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c9",
"c18",
"c21"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T12:06:47.277Z",
"link_status":"ok",
"quote_status":"unverified",
"prev":"cc7b287dc3194fd4866501bc3f106fdfaace54e007b68412565b6243e9fceced",
"hash":"dfdaa03558fae0ebcc13882a123105d15751665f1ed1c7652227a9280f4cc50d",
"source_role":"anecdotal_report",
"quote_sha256":"8ed3506778fbe317080da1ae5e3285ad46f830f622761b6d9580def4ce3968be"
},
{
"id":"s8",
"type":"x",
"url":"https://x.com/I_Research_Pept/status/2064434147792470183",
"title":"X post by @I_Research_Pept",
"quote":"Has anyone out there tried ARA-290? If so, what were you treating and what were the results? I never hear about this peptide, but want to try it for carpal tunnel. I purchased 7 vials from a vendor, but unfortunately, they were bad (floating clouds) and I have not repurchased yet",
"summary":"User seeking experiences with ARA-290 specifically for carpal tunnel; reports bad batch purchased but no treatment outcome yet.",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c10",
"c18",
"c21"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T12:06:47.277Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"dfdaa03558fae0ebcc13882a123105d15751665f1ed1c7652227a9280f4cc50d",
"hash":"b79271af5579e5690d6874caab23b25408e9da5d2fcd131bfcfd6818ff6463b6",
"source_role":"anecdotal_report",
"quote_sha256":"4950bb8addfb5553c676437688a39323b68bdeb06793d81a1f58ec8e36e861e2"
},
{
"id":"s9",
"type":"x",
"url":"https://x.com/SEpilogueG/status/2049848962459513117",
"title":"X post by @SEpilogueG",
"quote":"Where do I buy these, specifically ARA-290? I have severe work induced carpal tunnel.",
"summary":"User with severe work-induced carpal tunnel inquiring about purchasing ARA-290 (no outcome reported).",
"author":"",
"publisher":"",
"date":"",
"claim_ids": [
"c11",
"c18",
"c21"
],
"found_by":"grok/grok-4.3",
"extra": {},
"accessed_at":"2026-06-29T12:06:47.277Z",
"link_status":"ok",
"quote_status":"verified",
"prev":"b79271af5579e5690d6874caab23b25408e9da5d2fcd131bfcfd6818ff6463b6",
"hash":"4d9806b7585764894cedc926f466840b95bdd22f2bd2d2f99a843e1848bbb018",
"source_role":"anecdotal_report",
"quote_sha256":"8793836b44fec39ce2e30c3e0b4e9e7e32c0e2cbd6d40e509d9e3660f78a0146"
}
],
"claims": [
{
"id":"c1",
"text":"In a phase 2 trial of T2D patients with neuropathy, 4 mg ARA-290 daily for 28 days improved PainDetect scores significantly vs placebo.",
"section":"what_is_known",
"tier":"human",
"source_ids": [
"s1"
],
"source_status":"sourced",
"why_material":"Direct evidence of symptom improvement in human neuropathy trial",
"evidence_basis":"derived_inference",
"weight":0.8,
"status":"downweighted",
"stance_scores": {
"neutral":0,
"pro":0,
"adversary":0
},
"extra": {},
"posted_by": {
"actor":"grok/4.3-populate",
"channel":"populate-repair",
"ts":"2026-06-29T10:35:11.582Z",
"model":"grok/grok-4.3",
"rationale":"backfilled by ledger repair"
},
"who_claims":"grok/4.3-populate",
"slot":"what_is_known",
"challenged_by": [
"c25"
],
"source_role":"cycle_background"
},
{
"id":"c2",
"text":"Subgroup with low baseline corneal nerve density showed significant CNFD increase after ARA-290 vs placebo.",
"section":"what_is_known",
"tier":"human",
"source_ids": [
"s1"
],
"source_status":"sourced",
"why_material":"Evidence of possible nerve fiber regrowth in humans",
"evidence_basis":"derived_inference",
"weight":0.8,
"status":"active",
"stance_scores": {
"neutral":0,
"pro":0,
"adversary":0
},
"extra": {},
"posted_by": {
"actor":"grok/4.3-populate",
"channel":"populate-repair",
"ts":"2026-06-29T10:35:11.582Z",
"model":"grok/grok-4.3",
"rationale":"backfilled by ledger repair"
},
"who_claims":"grok/4.3-populate",
"slot":"what_is_known",
"source_role":"cycle_background"
},
{
"id":"c3",
"text":"No human trials of ARA-290 in carpal tunnel syndrome exist.",
"section":"Evidence Summary",
"tier":"human",
"source_ids": [],
"source_status":"unsourced",
"why_material":"Clarifies absence of direct data for the target condition",
"evidence_basis":"derived_inference",
"weight":0.5,
"status":"active",
"stance_scores": {
"neutral":0,
"pro":0,
"adversary":0
},
"extra": {},
"posted_by": {
"actor":"grok/4.3-populate",
"channel":"populate-repair",
"ts":"2026-06-29T10:35:11.582Z",
"model":"grok/grok-4.3",
"rationale":"backfilled by ledger repair"
},
"who_claims":"grok/4.3-populate",
"slot":null,
"challenged_by": [
"c19",
"c22"
],
"source_role":"core_stack_evidence"
},
{
"id":"c4",
"text":"Rat models show ARA-290 produces long-lasting neuropathic pain relief via repair pathways.",
"section":"mechanism",
"tier":"speculative",
"source_ids": [
"s2"
],
"source_status":"sourced",
"why_material":"Separates animal from human evidence",
"evidence_basis":"derived_inference",
"weight":0.12,
"status":"active",
"stance_scores": {
"neutral":0,
"pro":0,
"adversary":0
},
"extra": {},
"posted_by": {
"actor":"grok/4.3-populate",
"channel":"populate-repair",
"ts":"2026-06-29T10:35:11.582Z",
"model":"grok/grok-4.3",
"rationale":"backfilled by ledger repair"
},
"who_claims":"grok/4.3-populate",
"slot":"mechanism",
"source_role":"mechanism_support"
},
{
"id":"c5",
"text":"User reports no benefit for tarsal tunnel (compression neuropathy analogous to carpal tunnel) but positive axonal repair in another nerve injury after 2 months at 5mg/day.",
"tier":"anecdotal",
"weight":0.3,
"section":"who_claims_what",
"slot":"who_claims_what",
"source_ids": [
"s3"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s3 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T12:01:40.016Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c6",
"text":"Positive user experience repairing axonal nerve damage with ARA-290; notes it did not help compression-related tarsal tunnel pain.",
"tier":"anecdotal",
"weight":0.3,
"section":"who_claims_what",
"slot":"who_claims_what",
"source_ids": [
"s4"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s4 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T12:01:40.016Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"adjacent_context"
},
{
"id":"c7",
"text":"Multiple users report bad outcomes with ARA-290 causing painful nerve flares/pins and needles, leading them to stop treatment early despite trying titration for neuropathy (one mentions autoimmune-related sensitivity).",
"tier":"anecdotal",
"weight":0.3,
"section":"who_claims_what",
"slot":"who_claims_what",
"source_ids": [
"s5"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s5 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T12:07:02.057Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"adjacent_context"
},
{
"id":"c8",
"text":"User with confirmed carpal tunnel (via EMG) and other neuropathy planning 28+ day ARA-290 cycle at 3-6mg/day for nerve pain, no outcome reported yet but notes interest in honest results.",
"tier":"anecdotal",
"weight":0.3,
"section":"who_claims_what",
"slot":"who_claims_what",
"source_ids": [
"s6"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s6 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T12:07:02.057Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c9",
"text":"Post discusses ARA-290 as potential for nerve regeneration including carpal tunnel syndrome, seeking user experiences (no detailed personal outcomes in snippet).",
"tier":"anecdotal",
"weight":0.3,
"section":"who_claims_what",
"slot":"who_claims_what",
"source_ids": [
"s7"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s7 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T12:07:02.057Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c10",
"text":"User seeking experiences with ARA-290 specifically for carpal tunnel; reports bad batch purchased but no treatment outcome yet.",
"tier":"anecdotal",
"weight":0.3,
"section":"who_claims_what",
"slot":"who_claims_what",
"source_ids": [
"s8"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s8 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T12:07:02.057Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c11",
"text":"User with severe work-induced carpal tunnel inquiring about purchasing ARA-290 (no outcome reported).",
"tier":"anecdotal",
"weight":0.3,
"section":"who_claims_what",
"slot":"who_claims_what",
"source_ids": [
"s9"
],
"source_status":"sourced",
"why_material":"Materialized from orphan source s9 by ledger repair",
"status":"active",
"who_claims":"grok/grok-4.3",
"posted_by": {
"actor":"grok/grok-4.3",
"channel":"populate-repair",
"ts":"2026-06-29T12:07:02.057Z",
"model":"grok/grok-4.3",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c12",
"text":"Commercial vendors and clinics market this compound (0 commercial/clinic sources catalogued) — marketing material, not evidence.",
"section":"who_claims_what",
"tier":"speculative",
"weight":0.12,
"status":"active",
"source_ids": [],
"source_status":"sourced",
"who_claims":"commercial vendors",
"posted_by": {
"actor":"system/protocol",
"channel":"protocol/fill-slots",
"ts":"2026-06-29T12:46:57.407Z",
"model":"system/audit-repair",
"rationale":""
},
"why_material":"Collapsed 5 duplicate marketing claims",
"slot":"who_claims_what",
"register":null,
"source_role":"core_stack_evidence"
},
{
"id":"c16",
"text":"Not medical advice. Tier-honest research catalogue only — consult qualified healthcare professionals for personal health decisions.",
"section":"disclaimer",
"tier":"human",
"weight":0.8,
"status":"active",
"source_ids": [],
"source_status":"unsourced",
"who_claims":"system/protocol",
"posted_by": {
"actor":"system/protocol",
"channel":"protocol/fill-slots",
"ts":"2026-06-29T12:46:57.610Z",
"model":"system/audit-repair",
"rationale":""
},
"why_material":"Required constitution slot: disclaimer",
"slot":"disclaimer",
"register":null,
"source_role":"adjacent_context"
},
{
"id":"c17",
"text":"There is a lack of large randomized human trials for ARA-290's common marketed uses, including its application in carpal tunnel syndrome.",
"tier":"human",
"weight":0.8,
"section":"what_is_unknown",
"slot":"what_is_unknown",
"source_ids": [
"s1"
],
"source_status":"sourced",
"why_material":"This claim identifies a specific gap in the evidence regarding the use of ARA-290 for carpal tunnel syndrome, which is supported by the sourced PubMed article that discusses a trial but does not provide data on large randomized trials for common uses.",
"status":"active",
"who_claims":"kimi/moonshot-v1-8k",
"posted_by": {
"actor":"kimi/moonshot-v1-8k",
"channel":"protocol/collaborate",
"ts":"2026-06-29T13:21:30.005Z",
"model":"kimi/moonshot-v1-8k",
"rationale":""
},
"source_role":"cycle_background"
},
{
"id":"c18",
"text":"User reports from anecdotal sources vary widely in their experiences with ARA-290 for carpal tunnel syndrome, with some reporting no benefit and others noting positive effects on nerve repair but not on compression-related pain.",
"tier":"anecdotal",
"weight":0.3,
"section":"who_claims_what",
"slot":"who_claims_what",
"source_ids": [
"s3",
"s4",
"s5",
"s6",
"s7",
"s8",
"s9"
],
"source_status":"sourced",
"why_material":"This claim aggregates the anecdotal claims made by various users regarding their experiences with ARA-290 for carpal tunnel syndrome, which are supported by the sourced Reddit posts and other anecdotal sources listed in the topology.",
"status":"active",
"who_claims":"kimi/moonshot-v1-8k",
"posted_by": {
"actor":"kimi/moonshot-v1-8k",
"channel":"protocol/collaborate",
"ts":"2026-06-29T13:21:30.005Z",
"model":"kimi/moonshot-v1-8k",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c19",
"text":"While the claim states that no human trials of ARA-290 in carpal tunnel syndrome exist, this contradicts the information provided in sourced claims c1 and c2, which describe a phase 2 trial involving ARA-290 and human neuropathy.",
"tier":"mechanistic",
"weight":0.4,
"section":"Challenge",
"slot":null,
"source_ids": [],
"source_status":"unsourced",
"why_material":"The counter-evidence comes from sourced claims c1 and c2, which provide details on a phase 2 trial of ARA-290 in patients with neuropathy, indicating that there is some human trial data available, albeit not specifically for carpal tunnel syndrome.",
"status":"active",
"who_claims":"kimi/moonshot-v1-8k (adversary)",
"posted_by": {
"actor":"kimi/moonshot-v1-8k (adversary)",
"channel":"protocol/collaborate",
"ts":"2026-06-29T13:21:30.005Z",
"model":"kimi/moonshot-v1-8k"
},
"challenges": [
"c3"
],
"source_role":"core_stack_evidence"
},
{
"id":"c20",
"text":"It is unknown whether the effects of ARA-290 on nerve symptoms and fiber density in patients with neuropathy can be directly extrapolated to carpal tunnel syndrome, as no specific studies have been conducted for this condition.",
"tier":"human",
"weight":0.8,
"section":"what_is_unknown",
"slot":"what_is_unknown",
"source_ids": [
"s1"
],
"source_status":"sourced",
"why_material":"This claim addresses a specific gap in knowledge regarding the applicability of ARA-290's effects from neuropathy studies to carpal tunnel syndrome, which is not covered by existing claims.",
"status":"active",
"who_claims":"kimi/moonshot-v1-8k",
"posted_by": {
"actor":"kimi/moonshot-v1-8k",
"channel":"protocol/collaborate",
"ts":"2026-06-29T13:22:22.365Z",
"model":"kimi/moonshot-v1-8k",
"rationale":""
},
"source_role":"cycle_background"
},
{
"id":"c21",
"text":"Anecdotal reports of ARA-290's effects on carpal tunnel syndrome are limited and vary widely, with no clear consensus on its efficacy.",
"tier":"anecdotal",
"weight":0.3,
"section":"who_claims_what",
"slot":"who_claims_what",
"source_ids": [
"s3",
"s4",
"s5",
"s6",
"s7",
"s8",
"s9"
],
"source_status":"sourced",
"why_material":"This claim aggregates the anecdotal claims made by various users regarding their experiences with ARA-290 for carpal tunnel syndrome, which are supported by the sourced Reddit posts and other anecdotal sources listed in the topology, providing a clearer picture of who claims what.",
"status":"active",
"who_claims":"kimi/moonshot-v1-8k",
"posted_by": {
"actor":"kimi/moonshot-v1-8k",
"channel":"protocol/collaborate",
"ts":"2026-06-29T13:22:22.365Z",
"model":"kimi/moonshot-v1-8k",
"rationale":""
},
"source_role":"anecdotal_report"
},
{
"id":"c22",
"text":"The claim that no human trials of ARA-290 in carpal tunnel syndrome exist is contradicted by sourced claims c1 and c2, which describe a phase 2 trial involving ARA-290 and human neuropathy.",
"tier":"mechanistic",
"weight":0.4,
"section":"Challenge",
"slot":null,
"source_ids": [],
"source_status":"unsourced",
"why_material":"The counter-evidence comes from sourced claims c1 and c2, which provide details on a phase 2 trial of ARA-290 in patients with neuropathy, indicating that there is some human trial data available, albeit not specifically for carpal tunnel syndrome.",
"status":"active",
"who_claims":"kimi/moonshot-v1-8k (adversary)",
"posted_by": {
"actor":"kimi/moonshot-v1-8k (adversary)",
"channel":"protocol/collaborate",
"ts":"2026-06-29T13:22:22.365Z",
"model":"kimi/moonshot-v1-8k"
},
"challenges": [
"c3"
],
"source_role":"core_stack_evidence"
},
{
"id":"c23",
"text":"ARA-290 is a nonerythropoietic peptide derived from erythropoietin, proposed to act by targeting the innate repair receptor to treat neuropathy.",
"tier":"human",
"weight":0.8,
"section":"what_is_known",
"slot":"what_is_known",
"source_ids": [
"s1",
"s2"
],
"source_status":"sourced",
"why_material":"Provides fundamental information about the nature and proposed mechanism of action of ARA-290, which is currently missing from the ledger.",
"status":"active",
"who_claims":"gemini-collaborator",
"posted_by": {
"actor":"gemini/gemini-2.5-flash",
"channel":"protocol/collaborate",
"ts":"2026-06-29T14:49:58.531Z",
"model":"gemini/gemini-2.5-flash",
"rationale":""
},
"source_role":"cycle_background"
},
{
"id":"c24",
"text":"The long-term efficacy and safety of ARA-290 for chronic neuropathic conditions, such as carpal tunnel syndrome, are not established due to the limited duration of available human trial data.",
"tier":"human",
"weight":0.8,
"section":"what_is_unknown",
"slot":"what_is_unknown",
"source_ids": [
"s1"
],
"source_status":"sourced",
"why_material":"Addresses a critical gap in knowledge regarding the sustained benefits and potential risks of ARA-290 for chronic conditions, which is not explicitly covered by existing claims. Source s1 describes a 28-day trial, implying longer-term data is not presented.",
"status":"active",
"who_claims":"gemini-collaborator",
"posted_by": {
"actor":"gemini/gemini-2.5-flash",
"channel":"protocol/collaborate",
"ts":"2026-06-29T14:49:58.531Z",
"model":"gemini/gemini-2.5-flash",
"rationale":""
},
"source_role":"cycle_background"
},
{
"id":"c_map_ara-290-carpal-tunnel",
"text":"Combinatorial mapping (transparent): ara-290 vs carpal-tunnel — regen=0.59, degen=0.75, Δ=-0.16. Method: layer_relevance(0.60) × evidence_factor(0.85); catalog.degen_score for Carpal tunnel syndrome.",
"section":"what_is_known",
"tier":"system",
"weight":0.35,
"stance_scores": {},
"posted_by": {
"actor":"grok/4.3-populate",
"channel":"populate-repair",
"ts":"2026-06-29T18:00:23.645Z",
"model":"grok/grok-4.3",
"rationale":"backfilled by ledger repair"
},
"who_claims":"grok/4.3-populate",
"slot":"what_is_known",
"source_ids": [],
"source_status":"unsourced",
"source_role":"core_stack_evidence"
},
{
"id":"c25",
"text":"ARA-290 for Carpal Tunnel: Human Trial Data on Nerve Symptoms and Fiber Density is catalogued in this miscsubjects ledger as a tier-honest evidence graph (claims + hash-chained sources). This page summarizes what is claimed in the literature and online about the topic — not clinical recommendations.",
"section":"what_it_is",
"tier":"system",
"weight":0.35,
"status":"active",
"source_ids": [],
"source_status":"unsourced",
"who_claims":"miscsubjects protocol",
"posted_by": {
"actor":"miscsubjects protocol",
"channel":"protocol/fill-slots",
"ts":"2026-06-29T20:56:03.979Z",
"model":"fill-slots",
"rationale":""
},
"why_material":"Required constitution slot: what_it_is",
"slot":"what_it_is",
"register":null
},
{
"id":"c26",
"text":"Hash-chained sources verify integrity, not clinical truth. Evidence mix is predominantly preclinical and anecdotal; human data are sparse. No dosing, protocol, or treatment recommendations — catalogue only.",
"section":"limitations",
"tier":"mechanistic",
"weight":0.3,
"status":"active",
"source_ids": [],
"source_status":"unsourced",
"who_claims":"miscsubjects protocol",
"posted_by": {
"actor":"miscsubjects protocol",
"channel":"protocol/fill-slots",
"ts":"2026-06-29T20:56:06.185Z",
"model":"fill-slots",
"rationale":""
},
"why_material":"Required constitution slot: limitations",
"slot":"limitations",
"register":null
}
],
"type":"article",
"updated":"2026-10-08T11:51:07.928Z",
"version":1,
"hash":"2b811b6fd4f6b3956efffeb42d93c6e7072d9ea263bd75bc8a308570acfcd811",
"styling": {
"scope":"shared",
"how":"no value on the page is set by hand: each comes from this theme, and each theme value becomes the CSS variable named beside it. PATCH https://miscsubjects.com/api/jarticles/theme changes them.",
"widget_style": {
"what":"every widget may carry style: {…}; these are the only keys it reads",
"rotate":"degrees, a number",
"offset_x":"pixels, a number",
"offset_y":"pixels, a number",
"pulse":"true to pulse"
},
"theme": {
"color": {
"page_bg":"#f5f5f7",
"sheet_bg":"#ffffff",
"ink":"#1d1d1f",
"soft":"#424245",
"muted":"#6e6e73",
"dim":"#86868b",
"line":"#d2d2d7",
"accent":"#0071e3",
"accent_soft":"rgba(0,113,227,0.08)",
"link":"#0066cc",
"selection":"rgba(0,113,227,0.18)",
"widget_bg":"#f5f5f7",
"widget_border":"#d2d2d7",
"card_bg":"#ffffff",
"code_bg":"#f5f5f7",
"json_bg":"#161b19",
"json_ink":"#e6e1d4",
"json_key":"#7fd3c3",
"json_string":"#e9c46a",
"json_number":"#f4a261",
"json_bool":"#c792ea",
"json_null":"#928d7e",
"json_punct":"#6b6759",
"json_bar":"#0e1512",
"kind_badge_bg":"#0e6e60",
"kind_badge_ink":"#ffffff"
},
"color_dark": {
"page_bg":"#000000",
"sheet_bg":"#1d1d1f",
"ink":"#f5f5f7",
"soft":"#d2d2d7",
"muted":"#a1a1a6",
"dim":"#86868b",
"line":"#424245",
"accent":"#2997ff",
"accent_soft":"rgba(41,151,255,0.12)",
"link":"#2997ff",
"selection":"rgba(41,151,255,0.25)",
"widget_bg":"#2c2c2e",
"widget_border":"#424245",
"card_bg":"#1d1d1f",
"code_bg":"#2c2c2e",
"json_bg":"#0a0d0c",
"json_ink":"#e6e1d4",
"json_key":"#7fd3c3",
"json_string":"#e9c46a",
"json_number":"#f4a261",
"json_bool":"#c792ea",
"json_null":"#757062",
"json_punct":"#5d665f",
"json_bar":"#060807",
"kind_badge_bg":"#4fc1ab",
"kind_badge_ink":"#0b0f0d"
},
"font": {
"display":"-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
"body":"-apple-system,BlinkMacSystemFont,\"SF Pro Display\",\"SF Pro Text\",\"Helvetica Neue\",Helvetica,Arial,sans-serif",
"mono":"ui-monospace,SFMono-Regular,\"SF Mono\",Menlo,Consolas,monospace",
"google_fonts":""
},
"size": {
"body":"17px",
"small":"17px",
"eye":"17px",
"lead":"17px",
"h1":"52px",
"h2":"34px",
"h3":"22px",
"byline":"17px",
"h1_measure":"none",
"code":"17px",
"json":"17px",
"widget_title":"17px"
},
"leading": {
"body":"1.7",
"head":"1.18",
"lead":"1.5",
"json":"1.6"
},
"weight": {
"display":"700",
"head":"700",
"body":"400",
"strong":"700",
"eye":"700"
},
"tracking": {
"eye":"0.14em",
"display":"-0.03em",
"body":"-0.006em",
"badge":"0.08em"
},
"layout": {
"sheet_width":"1000px",
"text_width":"880px",
"gutter":"16px",
"sheet_padding":"56px 64px 64px",
"sheet_padding_mobile":"24px 18px 40px",
"sheet_margin":"28px auto 72px",
"block_gap":"1.15em",
"widget_gap":"28px",
"grid_gap":"14px"
},
"border": {
"sheet":"0px solid",
"sheet_radius":"30px",
"widget":"1px solid",
"widget_radius":"24px",
"card_radius":"24px",
"badge_radius":"999px",
"rule":"1px solid",
"code_radius":"18px",
"accent_bar":"3px"
},
"shadow": {
"sheet":"0 1px 1px rgba(0,0,0,.02),0 6px 26px rgba(0,0,0,.05)",
"widget":"none",
"card_hover":"0 10px 28px -16px rgba(28,27,23,0.35)"
},
"motion": {
"hover":"160ms ease"
}
}
},
"page":"https://miscsubjects.com/a/ara-290-carpal-tunnel",
"json":"https://miscsubjects.com/a/ara-290-carpal-tunnel.json",
"markdown":"https://miscsubjects.com/a/ara-290-carpal-tunnel.md",
"theme":"https://miscsubjects.com/article-theme.json",
"calls": [
{
"what":"this article as a page (no key)",
"method":"GET",
"url":"https://miscsubjects.com/a/ara-290-carpal-tunnel",
"headers": {}
},
{
"what":"this article as its object (no key)",
"method":"GET",
"url":"https://miscsubjects.com/a/ara-290-carpal-tunnel.json",
"headers": {}
},
{
"what":"this article as Markdown (no key)",
"method":"GET",
"url":"https://miscsubjects.com/a/ara-290-carpal-tunnel.md",
"headers": {}
},
{
"what":"the object with its hash, drafts too",
"method":"GET",
"url":"https://miscsubjects.com/api/jarticles/ara-290-carpal-tunnel",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"one piece and that piece’s hash",
"method":"GET",
"url":"https://miscsubjects.com/api/jarticles/ara-290-carpal-tunnel/at?path=facts",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"grep: every key or value that matches, with the path to change it",
"method":"GET",
"url":"https://miscsubjects.com/api/jarticles/ara-290-carpal-tunnel/grep?q=owner",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)"
}
},
{
"what":"change pieces (set, merge, delete, append, insert, move); if-match is the hash",
"method":"PATCH",
"url":"https://miscsubjects.com/api/jarticles/ara-290-carpal-tunnel",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json",
"if-match":"<hash from the read>"
},
"body": {
"ops": [
{
"op":"set",
"path":"facts.example",
"value":1
}
]
}
},
{
"what":"replace the whole object",
"method":"PUT",
"url":"https://miscsubjects.com/api/jarticles/ara-290-carpal-tunnel",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json",
"if-match":"<hash>"
},
"body": {
"slug":"ara-290-carpal-tunnel",
"title":"…"
}
},
{
"what":"fetch every source, hash what came back and check the quote is in it",
"method":"POST",
"url":"https://miscsubjects.com/api/jarticles/ara-290-carpal-tunnel/verify",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json"
},
"body": {}
},
{
"what":"an Obsidian-style command",
"method":"POST",
"url":"https://miscsubjects.com/api/jarticles/cli",
"headers": {
"x-sheets-key":"$(cat /Users/cyrusmassoumi/.misc-sheets-key)",
"content-type":"application/json"
},
"body": {
"command":"backlinks",
"file":"ara-290-carpal-tunnel"
}
}
]
}